- Selected as Excellent Company for Public Procurement by G-PASS (Government 

  Performance Assured), Republic of Korea.

- MOU signed with CIFF (Children's Investment Fund Foundation) for global HIV

  diagnosis partnership

- Business area expanded to Molecular Diagnosis

- Expansion of the 2^nd factory in Suwon (MDx Production Plant)
- Listed on EU Common list of COVID-19 antigen tests agreed by 

   EU Health Security Committee
- Established US entity

- MOU signed with Science and Technology Park, Pune for medical and 

  healthcare industry development

- Three rapid diagnostic kits (Malaria, Dengue, and Zika virus) selected as 

   next generation world-class products of KOREA

- Expansion of the 1^st factory in Suwon
  (RDT Production Plant / Monthly Capacity : 100 Mil tests)
- Acquired COVID-19 Ag Home Test Kit approval from Korea MFDS (1st and official)
- COVID-19 Ag for professional and home use is formally registered globally.
- Awarded with $100 million Export Tower in 2021 (Export reached $100 million in 2020)
- Acquired COVID-19 Ag Home Test Saliva Export Certification

- INNOBIZ Certification (Technology Innovation Enterprises)
- Global presence in over 50 countries around the world

- ISO 13485 : 2016 Certification
- Applied WHO PQ for 3 ERPD approved Malaria RDT
- Acquired MFDS/CE for 3 COVID-19 RDTs

- Acquired certification for 3 pLDH-based Malaria RDTs (GF ERPD)

- ISO 13485:2012 Certification

- KGMP Certification (by MFDS)

- Launched 20 types of IVD products for Human

- ISO 13485 Certification 

- Launched BIOCREDIT Influenza A&B Antigen

- Launched 10 Veterinary IVD products

- ISO 9001 Certification

- Development of Black Gold Particle Technology

- Established Rapigen R&D Center

- Establishment of Rapigen Co.,LTD